Randomized Phase Iii Trial of Utidelone, A Genetically Engineered Epothilone Analog, in Combination with Capecitabine Versus Capecitabine Alone for Metastatic Breast Cancer Patients with Previous Taxane and Anthracycline Treatment.
Binghe Xu,Tao Sun,Qingyuan Zhang,Zhongyu Yuan,Pin Zhang,Wang Xiao Jia,Shude Cui,Zefei Jiang,Yuee Teng,Xi-Chun Hu
DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.1004
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:1004 Background: Utidelone, a genetically engineered epothilone analog, is a microtubule stabilizing agent that showed promising activities in phase I and phase II trials. In this report, a multi-center, randomized phase III trial of utidelone plus capecitabine (CAP) vs CAP alone wascarried out to assess the efficacy and safety. Methods: Patients with metastatic breast cancer (MBC) previously treated with anthracycline and taxanes were randomized to utidelone (30mg/m2/d intravenously on d1-d5) plus CAP (1,000 mg/m2 orally bid on d1-d14) or CAP alone (1,250 mg/m2 orally bid on d1-d14) given every 21 days, until disease progression or unacceptable toxicity occurred. The two arms were enrolled with 2:1 ratio. The primary endpoint is progression-free survival (PFS); secondary endpoints include objective response rate (ORR), safety, and overall survival (available by 2017). PFS was estimated using the Kaplan-Meier product-limit method. Results: Of 405 patients randomized, about 80% had more than two prior chemotherapy regimens. Median of 6 and 5 cycles of utidelone plus CAP and CAP alone, respectively, were administered. The combination of utidelone with CAP was superior to CAP alone for both PFS (hazard ratio= 0.58; 95% CI, 0.44 to 0.75; log-rank P <0.0001) and ORR (39.4% with 2 complete responses vs 28.9% in the monotherapy arm). Utidelone plus CAP showed low level of liver and renal toxicities, and did not have significant increase in myelosuppression. Grade3/4 adverse events included peripheral neuropathy (14.2% in combination arm vs 0% in CAP alone), hand-foot syndrome (10% vs 6.7%), nausea (1.5% vs 1.5%), hyperbilirubinaemia (0% vs 1.5%), diarrhea (5% vs 0%), anaemia (3.1% vs 3%), leukopenia(4.2% vs 5.2%) and neutropenia (6.5% vs 5.2%). Conclusions: Utidelone plus CAP significantly improved PFS and ORR and had a manageable safety profile in this heavily pretreated population. It had very limited myelosuppression in addition to low liver and renal toxicities, in contrast to ixabepilone and other epothilone analogs. It offers a new potential therapeutic option for patients with MBC. Clinical trial information: NCT02253459.